Five G20 countries agree to build vaccine manufacturing center

Such a model is important to enable technology transfer to prepare for a pandemic (in the future).

Bali (ANTARA) – Five G20 members – Indonesia, Argentina, Brazil, India and South Africa – have agreed to collaborate to establish a vaccine manufacturing, processing and diagnostic center to mitigate future pandemics.

“To prepare for the next pandemic and global health threats, every country must have access to and have the capacity to develop vaccines, therapeutics and diagnostics (VTDs) regardless of economic status and geographic location,” Indonesian Health Minister Budi Gunadi Sadikin said. a press conference on the 3rd meeting of the Health Working Group (HWG) here on Monday.

The collaboration aims to initiate the strengthening of health tool manufacturing centers as well as the development of a global research center.

The minister said that the implementation of the initiative, which will focus on building health research and manufacturing capacity in middle-income countries, will involve all G20 member countries and international organizations.

The collaboration stems from the differences in capacity of each G20 country to deal with the COVID-19 pandemic.

Many vaccine platforms will be developed under the collaboration, including mRNA, viral vector, subunit protein with adjuvant and inactivated vaccines, Sadikin said.

Therefore, transfer of technology and knowledge between G20 countries is necessary to improve global access through the development of pharmaceutical manufacturing hubs, he added.

One example is the production of molnupiravir as an oral antiviral treatment for COVID-19 in lower-middle-income countries by the Medicines Patent Pool (MPP) facility.

“Such a model is important to enable technology transfer to prepare for a pandemic (in the future),” the minister remarked.

Related News: G20 backs Indonesia to release vaccine certificate verification system

The 3rd HWG meeting discussed expanding global manufacturing centers for vaccines, medicines and diagnostics in lower-middle-income countries, as well as strengthening the global network of public health researchers.

The meeting also promoted equitable access to vaccines by building research and development capacity, diversifying supply chains and strengthening collaboration between governments, the public and private sectors.

“Currently, no vaccines are produced by government industry. All are manufactured by private companies,” the minister noted.

Currently, the challenge facing the G20 forum is to develop and implement safe and effective diagnostics, therapies and vaccines for the international community within a maximum of 100 days, he added.

“This can only be achieved if all countries, whether high, middle or low income, have the capacity to produce or have equal access to vaccines, treatments and diagnostics,” he stressed. .

The G20 is preparing the Global Initiative on Sharing All Influenza Data Plus (GISAID+) platform to accelerate mitigation and data collection on highly infectious pathogens, he added.

Related News: Indonesia emphasizes global vaccine equality to fight COVID-19
Related news: Need for equitable distribution of health resources for better health services

Previous Britons are facing substantial increases in their energy bills. here's why
Next Get ready to win a bigger share of the EU export market: experts